Sumitomo Pharma Statistics

Total Valuation

Sumitomo Pharma has a market cap or net worth of JPY 749.88 billion. The enterprise value is 951.51 billion.

Market Cap	749.88B
Enterprise Value	951.51B

Important Dates

The next estimated earnings date is Wednesday, May 13, 2026.

Earnings Date	May 13, 2026
Ex-Dividend Date	n/a

Share Statistics

Sumitomo Pharma has 397.29 million shares outstanding.

Current Share Class	397.29M
Shares Outstanding	397.29M
Shares Change (YoY)	n/a
Shares Change (QoQ)	+0.00%
Owned by Insiders (%)	0.04%
Owned by Institutions (%)	13.65%
Float	183.27M

Valuation Ratios

The trailing PE ratio is 6.81 and the forward PE ratio is 8.38. Sumitomo Pharma's PEG ratio is 0.35.

PE Ratio	6.81
Forward PE	8.38
PS Ratio	1.65
PB Ratio	2.60
P/TBV Ratio	n/a
P/FCF Ratio	15.92
P/OCF Ratio	14.08
PEG Ratio	0.35

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 7.30, with an EV/FCF ratio of 20.21.

EV / Earnings	8.64
EV / Sales	2.10
EV / EBITDA	7.30
EV / EBIT	8.76
EV / FCF	20.21

Financial Position

The company has a current ratio of 1.40, with a Debt / Equity ratio of 0.90.

Current Ratio	1.40
Quick Ratio	0.91
Debt / Equity	0.90
Debt / EBITDA	1.99
Debt / FCF	5.50
Interest Coverage	3.59

Financial Efficiency

Return on equity (ROE) is 48.39% and return on invested capital (ROIC) is 22.11%.

Return on Equity (ROE)	48.39%
Return on Assets (ROA)	8.12%
Return on Invested Capital (ROIC)	22.11%
Return on Capital Employed (ROCE)	17.95%
Weighted Average Cost of Capital (WACC)	7.40%
Revenue Per Employee	118.32M
Profits Per Employee	28.73M
Employee Count	3,832
Asset Turnover	0.54
Inventory Turnover	1.95

Taxes

Income Tax	-14.97B
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +175.84% in the last 52 weeks. The beta is 0.46, so Sumitomo Pharma's price volatility has been lower than the market average.

Beta (5Y)	0.46
52-Week Price Change	+175.84%
50-Day Moving Average	2,425.34
200-Day Moving Average	1,743.78
Relative Strength Index (RSI)	37.13
Average Volume (20 Days)	16,670,705

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Sumitomo Pharma had revenue of JPY 453.40 billion and earned 110.09 billion in profits. Earnings per share was 277.11.

Revenue	453.40B
Gross Profit	268.59B
Operating Income	108.40B
Pretax Income	95.12B
Net Income	110.09B
EBITDA	130.00B
EBIT	108.40B
Earnings Per Share (EPS)	277.11

Full Income Statement

Balance Sheet

The company has 57.32 billion in cash and 258.95 billion in debt, giving a net cash position of -201.63 billion or -507.52 per share.

Cash & Cash Equivalents	57.32B
Total Debt	258.95B
Net Cash	-201.63B
Net Cash Per Share	-507.52
Equity (Book Value)	288.94B
Book Value Per Share	727.28
Working Capital	84.14B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 53.28 billion and capital expenditures -6.19 billion, giving a free cash flow of 47.09 billion.

Operating Cash Flow	53.28B
Capital Expenditures	-6.19B
Free Cash Flow	47.09B
FCF Per Share	118.53

Full Cash Flow Statement

Margins

Gross margin is 59.24%, with operating and profit margins of 23.91% and 24.28%.

Gross Margin	59.24%
Operating Margin	23.91%
Pretax Margin	20.98%
Profit Margin	24.28%
EBITDA Margin	28.67%
EBIT Margin	23.91%
FCF Margin	10.39%

Dividends & Yields

Sumitomo Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	0.00%
Buyback Yield	n/a
Shareholder Yield	n/a
Earnings Yield	14.68%
FCF Yield	6.28%

Dividend Details

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Sumitomo Pharma has an Altman Z-Score of 1.96 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.96
Piotroski F-Score	5